Activating EGFR mutant kinase were detected using 18F-MPG in patients with non-small cell lung cancer (NSCLC) and it was demonstrated that patients with a high uptake of 18F-MPG (SUV > 2.23) had a greater response to EGFR-TKIs (>80% versus 6%) and twice longer median progression-free survival [156]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.